FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to lyophilized compositions of lysyl-prolyl-threonine, in particular to lyophilized L-lysyl-D-prolyl-L-threonine compositions which are stable during storage, as well as to a method of producing said lyophilized compositions.
EFFECT: present invention refers to pharmaceutical and cosmetic compositions containing lyophilized compositions which are used in therapeutic and/or preventive treatment, for diagnosis and/or therapy of pain-related diseases, itching diseases, inflammatory diseases and/or other diseases in mammals.
7 cl, 2 dwg, 4 ex, 7 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| FORMULATIONS CONTAINING ANTIBODIES | 2009 |
|
RU2745601C2 |
| NEW STABLE COMPOSITIONS FOR FXIA ANTIBODIES | 2018 |
|
RU2775692C2 |
| AQUEOUS PHARMACEUTICAL COMPOSITION OF ANTIBODY TO PD-1 OF PROLGOLIMAB AND ITS USE | 2019 |
|
RU2806320C2 |
| PHARMACEUTICAL COMPOSITION BASED ON IL-15 PROTEIN COMPLEX AND APPLICATIONS THEREOF | 2018 |
|
RU2749342C1 |
| PHARMACEUTICAL COMPOSITION | 2017 |
|
RU2775944C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODY TO SOST, AND ITS USE | 2018 |
|
RU2779430C2 |
| FORMULATIONS BASED ON CD19 ANTIBODY | 2017 |
|
RU2748024C2 |
| GM-CSF-NEUTRALIZING ANTIBODIES FOR USE IN TREATING RHEUMATOID ARTHRITIS OR AS ANALGESICS | 2014 |
|
RU2714919C2 |
| COMBINATION DRUG CONTAINING CORTICOSTEROID AND EXOSOMES | 2010 |
|
RU2557897C2 |
| AQUEOUS PHARMACEUTICAL COMPOSITION OF ANTI-IL17A ANTIBODY AND ITS APPLICATION | 2019 |
|
RU2754760C2 |
